A new therapeutic approach
We are developing oral Live Biotherapeutic candidates designed to address gut–immune–brain pathways relevant to cognition, neuroinflammation and neurodegeneration.
Our approachFrom biology to human evidence
Our clinical strategy is biomarker-informed: it is designed to generate human biological evidence first, and to let that evidence guide subsequent indication development.
Clinical strategyWhy the gut–immune–brain axis?
Independent research increasingly connects the gut microbiome with immune, metabolic and central nervous system biology, creating new possibilities for therapeutic intervention in Brain Health.
Explore the pathwaysThe clinical need
Therapeutic options remain limited for people living with cognitive impairment.
Cognitive impairment occurs across several central nervous system disease contexts. In several neurodegenerative conditions, biological changes can precede clinical diagnosis by years. Available treatments remain limited.
Neurodegeneration and neuroinflammation are widely described as multifactorial processes, and no single mechanism accounts for them. Additional therapeutic approaches are needed.
Explore our scienceOur scientific rationale
Exploring gut–immune–brain biology to develop new therapeutic options for Brain Health.
A growing body of independent research supports a relationship between the gut microbiome and biological processes relevant to Brain Health. NBX is developing defined Live Biotherapeutic candidates through a proprietary discovery and development approach.
-
Defined Live Biotherapeutics
NBX develops carefully characterized Live Biotherapeutic candidates intended for pharmaceutical development.
-
Proprietary development approach
Our programs are built on proprietary research and development conducted in-house and with academic partners.
-
Planned clinical development
Our objective is to advance a new therapeutic approach toward clinical evaluation, with cognitive impairment as the planned clinical entry phenotype across selected Brain Health conditions.
Independent peer-reviewed studies informing this field are summarized on our literature page.
Explore our scienceLead program
Preclinical
Oral Live Biotherapeutic
NBX-5831: an oral Live Biotherapeutic candidate for Brain Health.
NBX-5831 is an oral Live Biotherapeutic candidate being developed through a biomarker-informed Brain Health strategy. The initial clinical strategy is built around cognitive impairment, including MCI, as a clinically relevant entry phenotype.
View the NBX-5831 programPlanned clinical development
Advancing a new therapeutic approach for Brain Health.
NBX is developing oral Live Biotherapeutic candidates for Brain Health. Early clinical development is intended to generate human biological evidence and to help identify the patient profiles and disease contexts in which NBX-5831 may have the greatest development potential.
View the NBX-5831 programComplementary expertise
Scientific depth, clinical guidance and biotechnology execution.
NBX combines internal leadership with external scientific, strategic and business advisors experienced in microbiome science, neuroscience, clinical development, regulatory affairs and company building.
Meet the team and advisors- Microbiome therapeutics
- Neuropharmacology
- Metabolomics
- Clinical development
- Biotechnology strategy
- Regulatory affairs
Partnerships · Investment · Research
Help us translate gut–immune–brain biology into therapeutic development.
NBX welcomes discussions with scientific collaborators, clinical experts, development partners and investors interested in advancing microbiome-derived therapeutics for Brain Health.
Our science
Developing Live Biotherapeutics for Brain Health through the gut–immune–brain axis.
A growing body of independent research supports a relationship between the gut microbiome and biological processes relevant to Brain Health. NBX Biosciences is developing defined Live Biotherapeutic candidates through a proprietary discovery and development approach. All programs are currently preclinical.
01 · The clinical need
Cognitive impairment remains an area of substantial unmet need across multiple CNS conditions.
Cognitive impairment occurs across several central nervous system disease contexts, potentially including Alzheimer's disease, Parkinson's disease, major depressive disorder and other Brain Health conditions. In several neurodegenerative conditions, biological changes can precede clinical diagnosis by years, and therapeutic options remain limited.
Established research describes neurodegeneration and neuroinflammation as multifactorial processes. No single mechanism accounts for them, which is one reason additional therapeutic approaches are needed.
02 · The gut–immune–brain axis
A biological axis connecting the gut ecosystem to pathways relevant to cognition.
NBX-5831 is being developed within this biological framework. Its candidate-specific mechanisms of action remain under investigation. The objective of our development program is to establish human biological evidence in patients.
The pathways described below are drawn from independent published research and are presented as scientific context. They are not presented as established mechanisms of action for NBX-5831.
-
Gut
Microbial functions and ecosystem
The composition and functional output of the intestinal microbial ecosystem.
-
Immune & systemic biology
Inflammatory and metabolic signaling
Immune and metabolic signals that may contribute to communication between the gut and the central nervous system.
-
Brain
Pathways relevant to cognition
Biology associated with cognition, neuroinflammation and neurodegeneration.
03 · Our approach
A focused Live Biotherapeutic development approach.
-
Scientific foundation
Independent research increasingly connects the gut microbiome with Brain Health and neurodegenerative biology.
-
Defined Live Biotherapeutics
NBX develops carefully characterized Live Biotherapeutic candidates intended for pharmaceutical development.
-
Preclinical development
Our programs are progressing through preclinical development toward potential future clinical evaluation.
Independent peer-reviewed studies providing scientific context for this field are summarized on our literature page.
Scientific literature04 · Clinical strategy
A biomarker-informed clinical strategy
NBX's planned early clinical development strategy is designed to generate human evidence by studying patients with cognitive impairment while characterizing their underlying clinical and biological profiles.
The objective is to evaluate safety, biological engagement and biomarker and clinical patterns that can guide subsequent clinical development.
-
Human biological evidence
Establish whether NBX-5831 engages relevant biology in patients.
-
Patient stratification
Explore biological and clinical characteristics associated with observed biomarker and clinical signals.
-
Indication strategy
Use human data to inform subsequent Brain Health development.
NBX-5831 remains at a preclinical stage and has not yet been evaluated in clinical trials. Its safety and efficacy in humans have not been established. Any future clinical evaluation will be subject to regulatory authorization.
05 · Human translational evidence
Building human relevance ahead of clinical development.
NBX is leveraging clinically annotated human cohorts and metagenomic data to explore the relationship between NBX-5831, cognitive phenotype, disease stage and relevant human biology.
- Assess human relevance
- Explore clinically relevant associations
- Inform patient-stratification hypotheses
- Support clinical-development strategy
This work is translational research. Associations observed in human cohorts do not by themselves establish causality, and they do not establish the safety or efficacy of NBX-5831.
06 · Development status
A lead program at a preclinical stage of development.
Our lead candidate, NBX-5831, is a defined oral Live Biotherapeutic candidate for Brain Health. It is progressing through preclinical development, with cognitive impairment, including MCI, as the planned clinical entry phenotype, subject to regulatory authorization and financing.
Current stage
Preclinical
All candidates are preclinical; no NBX product holds a marketing authorization.
Our team
A multidisciplinary team guiding NBX from microbiome science toward clinical development.
Experienced team combining microbiome, CNS, clinical and business expertise to advance NBX-5831 from translation to development.
Executive leadership
-
{{ p.name }}
{{ p.role }}
{{ p.bio }}
R&D and operations
-
{{ p.name }}
{{ p.role }}
{{ p.bio }}
Scientific, strategic & business advisors
NBX is supported by external experts whose complementary expertise spans microbiome R&D, neuropharmacology, strategy and business development. They act in an advisory capacity and are not employees of NBX Biosciences.
-
{{ a.kind }}
{{ a.name }}
{{ a.domain }}
{{ a.bio }}
News
Company & science news
{{ n.dateLabel }}
{{ n.category }}
There is no announcement to report at present. For information on the program, please contact us.
Careers
Speculative applications
NBX Biosciences is a small team based in Montpellier, working at the intersection of microbiology, immunology and neuroscience.
No vacancy is open at present
We do read speculative applications, including for internships, apprenticeships and doctoral or post-doctoral collaborations. If your background is in microbiome research, immunology, neuroscience, regulatory affairs or bioprocess development, send a CV and a short note on the work that interests you.
Send a speculative application141 rue de la Cardonille, 34090 Montpellier, France.
Contact
Get in touch
Write to us at the address below, or use the subject that matches your inquiry so it reaches the right person directly.
Start a conversation with NBX
We welcome discussions with investors, development partners, scientific and clinical collaborators, and members of the media.
- Partnerships and investment
- Scientific and clinical collaborations
- Press and general inquiries
Looking to join the team? See speculative applications.
Lead program
NBX-5831
NBX-5831 is an oral Live Biotherapeutic candidate being developed across Brain Health through the gut–immune–brain axis. The initial clinical strategy is built around cognitive impairment, including MCI, as a clinically relevant entry phenotype, rather than committing upfront to one disease-specific development path.
Lead candidate
Preclinical
Development pipeline
Advancing NBX-5831 toward clinical evaluation
NBX is advancing its lead program through preclinical development, while preparing the product-development and regulatory foundations required for future evaluation.
Program
Discovery
Preclinical
Phase I
Phase II/III
Brain Health
NBX-5831
Oral Live Biotherapeutic candidate for Brain Health
Planned clinical entry: cognitive impairment, including MCI
Preclinical
NBX-5831 is at a preclinical stage of development. Alzheimer's disease, Parkinson's disease and major depressive disorder are potential disease contexts, not separate programs in clinical development.
NBX-5831 is a preclinical investigational candidate. Its safety and efficacy have not been established, and future development remains subject to scientific, regulatory and financing milestones.
Brain Health development strategy
A data-driven path from clinical entry to indication strategy
Rather than committing upfront to a single disease-specific development path, NBX intends to enter clinical development through cognitive impairment and to use the human evidence generated to inform where NBX-5831 may have the greatest development potential.
-
Cognitive impairment, including MCI
Planned clinical entry through a clinically relevant phenotype that occurs across several Brain Health conditions.
-
Human biological evidence
Evaluate biological engagement and clinically relevant signals.
-
Patient stratification
Explore biological and clinical characteristics associated with observed biomarker and clinical signals.
-
Data-driven development
Inform future indication and patient-selection strategies.
Potential disease contexts include Alzheimer's disease, Parkinson's disease, major depressive disorder and other conditions associated with cognitive impairment. These are potential disease contexts, not committed clinical programs.
Development logic
From candidate to a data-driven Brain Health indication strategy
NBX-5831
Cognitive impairment, including MCI
Human biological evidence
Patient stratification
Data-driven Brain Health development
Long-term strategic focus
Alzheimer's disease
Additional Brain Health opportunities, subject to human data
Parkinson's disease · Major depressive disorder · Other high-unmet-need CNS conditions
Alzheimer's disease
A long-term strategic focus.
Alzheimer's disease remains a major area of strategic interest for NBX because of its high unmet medical need and the growing evidence linking gut, immune and CNS biology.
NBX's development strategy is designed to build human evidence progressively and inform the most relevant path toward Alzheimer's disease and other Brain Health conditions.
Program snapshot
- Candidate
- NBX-5831
- Modality
- Oral Live Biotherapeutic candidate
- Current stage
- Preclinical
- Planned clinical entry
- Cognitive impairment, including MCI
Program status is maintained by NBX Biosciences and reflects the current stage of development. No dates, timelines, study designs or patient numbers are published; the sequence remains subject to scientific, regulatory and financing milestones. No NBX product holds a marketing authorization. Further information on NBX-5831, including its biological characterization, is shared with partners under confidentiality.
Scientific literature
Gut–brain science across Brain Health
Research across Alzheimer's disease, Parkinson's disease, depression and multiple sclerosis — together with studies of cognitive aging and perioperative cognition — is examining how gut-derived signals may interact with immune and brain function.
Explore the published evidence behind metabolic, immune and neural pathways relevant to Brain Health.
These publications support the scientific rationale for the field. They do not evaluate NBX-5831 or establish its safety, efficacy or mechanisms of action.
Literature reviewed: September 2026
Key publications
Three independent peer-reviewed publications supporting the biological rationale behind NBX's approach. None of them evaluates NBX-5831.
-
{{ k.label }}
{{ k.journal }} · {{ k.year }}
{{ k.title }}
{{ k.authors }}
Pathways highlighted
{{ k.chain }}
Why it matters
{{ k.why }}
{{ k.cta }}
The science is converging
The gut microbiome is increasingly being investigated as a modulator of neuroinflammatory processes.
A 2026 review in The Lancet Neurology highlights multiple gut-to-brain pathways including immune regulation, microbial metabolites, intestinal and blood–brain barrier integrity, vagal signaling and bile-acid signaling.
Together with growing human evidence in mild cognitive impairment and Alzheimer's disease, these findings reinforce the scientific rationale for investigating precisely defined microbiome-derived therapeutics in neurological disorders.
Gut
Microbiome
Signals
Metabolites · Immune signaling · Vagus
Brain
Neuroinflammation
Pathways discussed in the review
- Immune regulation
- Microbial metabolites
- Barrier integrity
- Vagal signaling
- Bile acids
Biological pathways
Different signals. Connected biology.
Three groups of signals are studied in the published literature. They are distinct, they are investigated with different methods, and the evidence linking them differs in strength. Selecting a pathway filters the bibliography below.
Intestine
Microbial metabolism and barrier function
Systemic
Circulating microbial products and immune responses
Brain
Neuroinflammation and hippocampal function
Metabolites and microbial products reach systemic circulation
Immune and metabolic signals interact with brain biology
Ascending vagal signaling, studied experimentally in animals
-
{{ c.n }}
{{ c.label }}
{{ c.body }}
{{ c.count }}
Highlights
Studies that connect the biology
-
{{ f.id }} {{ f.badge }}
{{ f.flag }} {{ f.headline }}
{{ f.meta }}
{{ f.kf }}
Disease contexts
Shared pathways across different conditions
These are contexts in the published literature, not indications in NBX development. Cognitive aging is a research context rather than a disease, and MCI is a clinical phenotype rather than a synonym for Alzheimer's disease.
{{ ctxLabel }}
{{ ctxText }}
Selected references
Bibliography
Explore the publications
Twenty-seven references, selected in September 2026 to cover mechanistic manipulation, experimental transfer, human observation and early intervention, including results that are negative or context-dependent. Pathway tags indicate a subject under study, not a causally validated route.
Disease context
Pathway
Evidence type
{{ litCount }}
{{ litRange }}
No studies match these filters
No study in this selection combines the criteria you chose. Empty combinations are expected: the selection does not claim that every pathway has been studied in every condition.
-
{{ pub.id }}
{{ pub.meta }}
DOI: {{ pub.doi }}
From published biology to therapeutic development
Together, these studies support investigating the gut–immune–brain axis across Brain Health. They also show why therapeutic development requires a defined intervention, biological characterization and evidence generated in the intended patient population.
NBX Biosciences is developing NBX-5831, an oral Live Biotherapeutic candidate, through a biomarker-informed Brain Health strategy. Candidate-specific biological activity, safety and clinical benefit require dedicated evaluation.
NBX-5831 · Preclinical
Legal
Legal notice
Publisher
NBX BIOSCIENCES SAS, a French société par actions simplifiée with share capital of €1 266,20.
Registered office: 141 rue de la Cardonille, 34090 Montpellier, France.
SIREN: 949 527 436. Registered with the Montpellier Trade and Companies Register: 949 527 436 R.C.S. Montpellier.
SIRET (registered office): 949 527 436 00024. EU VAT number: FR04949527436.
APE/NAF code: 72.19Z, research and development in other physical and natural sciences.
Legal representative and publication director: Damien Rei, President.
Contact: admin@nbxbiosciences.com.
Hosting
This site is hosted by o2switch, Chemin des Pardiaux, 63000 Clermont-Ferrand, France. Telephone: +33 (0)4 44 44 60 40.
Intellectual property
The site as a whole, and each of its elements — the NBX name and logo, texts, graphics, images and scientific illustrations — are the exclusive property of NBX BIOSCIENCES or of its licensors, and are protected by French and international intellectual property law. Any reproduction, representation, adaptation or use, in whole or in part, is prohibited without prior written authorization.
Information published on this site
The scientific and corporate information published here is provided for information purposes only and describes research and development activities at a preclinical stage. It does not constitute medical advice, a therapeutic claim, the promotion of any medicinal product, or an offer to invest. No product developed by NBX BIOSCIENCES holds a marketing authorization. Patients should consult a healthcare professional.
Liability
NBX BIOSCIENCES takes care to keep the information published on this site accurate and up to date, but gives no warranty as to its completeness or accuracy, and accepts no liability for any direct or indirect damage arising from access to or use of the site, or from the content of third-party sites reached through links published here.
Applicable law
This legal notice is governed by French law. Any dispute relating to the site falls within the jurisdiction of the competent French courts.
Legal
Privacy policy
This policy explains how NBX BIOSCIENCES processes personal data in connection with this website, in accordance with Regulation (EU) 2016/679 (GDPR) and the French Data Protection Act.
Controller
NBX BIOSCIENCES, 141 rue de la Cardonille, 34090 Montpellier, France. For any question relating to personal data: admin@nbxbiosciences.com.
What we process and why
Inquiries sent by email. The content of your message and the contact details it contains. Purpose: answering your inquiry. Legal basis: our legitimate interest in responding to people who contact us. Retention: three years from the last contact.
Applications. The CV, cover letter and any information you send us. Purpose: assessing your application. Legal basis: your consent. Retention: two years from the last contact, unless you ask us to delete it sooner.
Technical data. Data strictly necessary to serve the site, such as server logs. Purpose: security and availability. Legal basis: legitimate interest.
Cookies
This site uses no advertising or audience-measurement cookies. Should a non-essential cookie be introduced, consent will be requested before it is placed.
Recipients
Your data is accessible to the NBX BIOSCIENCES staff who need it in order to answer you, and to the technical service providers who host the site and our email, acting as processors under contract. It is never sold or transferred for commercial purposes.
Your rights
You have the right to access, rectify, erase and port your data, to restrict or object to its processing, and to withdraw your consent at any time. Write to admin@nbxbiosciences.com; we answer within one month. If you consider that your rights are not respected, you may lodge a complaint with the CNIL, www.cnil.fr.
Security
We apply appropriate technical and organizational measures to protect your data against unauthorized access, loss or alteration.